Retaining U.S. marketing rights for itself, Acusphere Inc. signed a deal with Nycomed Group for the European rights to its lead product, AI-700. (BioWorld Today)

LONDON - Cyclacel Group plc announced a dual listing on Nasdaq and the London Stock Exchange seeking £26.6 million (US$48 million) to charge development of the lead compound from its orally available cyclin dependent kinase inhibitor program in a bid to be first to market. (BioWorld International)

Looking to boost the value of its recent cancer deal with XOMA Ltd., Chiron Corp. is acquiring Sagres Discovery Inc. for undisclosed terms. (BioWorld Today)